AERI Aerie Pharmaceuticals Inc.

-0.61  -2%
Previous Close 39.78
Open 39.62
Price To Book 7.9
Market Cap 1798677587
Shares 45,919,775
Volume 623,975
Short Ratio
Av. Daily Volume 735,200

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced March 12, 2019.
PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.

Latest News

  1. Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside
  2. Have Insiders Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares This Year?
  3. Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
  4. Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe
  5. Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?
  6. Aerie (AERI) Down 2.9% Since Last Earnings Report: Can It Rebound?
  7. Aerie Pharmaceuticals Announces Four Appointments
  8. Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
  9. Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
  10. Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion
  11. Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
  12. The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie
  13. Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance
  14. Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
  15. Introducing Aerie Pharmaceuticals, The Stock That Zoomed 271% In The Last Three Years
  16. See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
  17. Aerie Pharmaceuticals to Present at Two Investor Conferences in March
  18. New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel — Consolidated Revenues, Company Growth, and Expectations for 2019
  19. Edited Transcript of AERI earnings conference call or presentation 25-Feb-19 10:00pm GMT
  20. Aerie (AERI) Q4 Earnings Miss, Rhopressa Gains Traction